Allurion Technologies Inc. has been granted two U.S. patents for its innovative balloon technology aimed at treating obesity. The new patents—U.S. Patent No. 12,246,163, titled “Automatic-Sealing Balloon-Filling Catheter System,” and U.S. Patent No. 12,245,962, titled “Balloon Sealing and Fill Valve”—cover improvements in the balloon’s filling mechanism and valve control. These patents are effective through April 2043.
With these two recent additions, Allurion now holds 64 patents worldwide, including 22 in the United States.
The Allurion Program combines several components to help with weight loss. This includes the Allurion Gastric Balloon, which is the world’s first swallowable gastric balloon that requires no procedure for insertion. The platform also features the Allurion Virtual Care Suite, which includes the Allurion Mobile App, Connected Scale, and Allurion Insights for healthcare providers, powered by the Iris AI Platform. Patients using the Allurion Program typically lose 10% to 15% of their total body weight, with some studies showing increased muscle mass as well.
“Allurion is focused on continuous innovation as we move forward with clinical trials to combine our balloon with GLP-1 therapy. Our goal is to set a new standard in obesity treatment,” said Shantanu Gaur, Founder and CEO of Allurion.
The Allurion Virtual Care Suite is available to healthcare providers separately, allowing them to customize and manage weight-loss therapy for patients, regardless of the treatment plan. The Allurion Gastric Balloon is currently an investigational device in the United States.
